Clinical Research Trials for Clinical Research Professionals (CRP)

1. A Phase III Multi-Center Randomized Double-Blind, Placebo-Controlled Trial of the Ex-Vivo Treatment with CGT003 of Peripheral Vein Grafts in Patients Undergoing **Peripheral Arterial Bypass Graft Procedures**, Protocol #CGTOOJ-03
2. A Randomized Controlled Clinical Trial of the Effect of a High Dose Combination of Folic Acid, Vitamin B6 and B12, on **Arteriosclerotic Cardiovascular Disease** Outcomes in Chronic, Stable Renal Transplant Recipients. (An Ancillary Study of the FAVORIT trial)
3. A Randomized, Double-Blind, Placebo Controlled, Multi-Center Safety and Efficacy Trial of LJP 394 in **Systematic Lupus Erythematosus** (SLE) Patients with a History of Renal Disease. Protocol # UP 394-90-10
4. An Open-Label, Multi-Center, Long-Term Continuation, Safety Trial of LJP 394 in **Systematic Lupus Erythematosus** (SLE) Patients with a History of Renal Disease. Protocol # UP 394-90-10
5. Multi-Center, Randomized, Double Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Oral Tolvaptan in Patients with **Hyponatremia**. Protocol # I56-02-235
6. A Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Trial of CII Oral Tolerance Induction in **Rheumatoid Arthritis** Patients of NSAIDs.
7. Epidemiologic Study of the Natural History of **Fabry Disease**. Protocol # AGAL-014-01
8. Endoscopic Delivery of Energy to the Gastric Cardia for the Treatment of **Gastroesophageal Reflux Disease**, the Stretta Procedure.
9. An Efficacy and Safety Study of Intravenous Pantroprazole in the Prevention of **Recurrent Peptic Ulcer Bleeding** after Successful Hemostasis. Protocol # 3001 K2-3/5-CJS
10. An Evaluation of the Endonetics Gatekeeper System, in the Treatment of Patients with **Gastroesophageal Disease (GERD).**
11. Safety and Efficacy of Recombinant Human Interleukin-10 (TENOVI L) in Prevention of **Post-ECRP Acute Pancreatitis** in Subjects with Increased Risk.
12. A Phase II, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients with **Invasive Candidiasis**.

13. Clinical Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Parallel, Multi dose comparison of the Effects of Celecoxib 200mg BID and Placebo in Patients with **Ulcerative Colitis** in Remission.

14. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Trial Evaluation the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with **Plaque-type Psoriasis**.

15. A Double-Blind, Randomized, Controlled Study to Evaluation the Immunogenicity and Safety of XXX **Herpes Simplex Candidate Vaccine**, (XXX) in Healthy HSY Seronegative and Seropositive Female Subjects (10-17 years old).

16. A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Single Dose Study to Evaluate the Safety and Efficacy of XXX in Acute Treatment of **Migraine Headaches**.

17. An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of **Acute Migraine** over 12 months.

18. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 18 month Study of the Efficacy of XXX, in Patients with **Mild-to-Moderate Dementia of the Alzheimer's type**.

19. A Double-Blind, Placebo-Controlled, 12 Week Safety Study to Assess the Effect of XXX (100mg QD) on **Spermatogenesis and Reproductive Endocrine Parameter in Healthy Adult Male Subjects**.

20. A Safety and Efficacy Study of Subjects with **Age Associated Memory Impairment (AAMI).**

21. A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Subjective Response to Treatment with Ramelteon (XXX) in Adult Subjects with **Chronic Insomnia** by Utilizing an Interactive Voice Response (IVRS) for Collecting Diary Data.

22. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of- Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCi (ACTOS) in Combination with XXX in Subjects with **Type 2 Diabetes**.

23. A 24 Week Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with **Type 2 Diabetes** Poorly Controlled on Insulin.

24. A Double-Blind, Randomized, Placebo-Controlled 4 Week Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX and its Active Metabolite, in Subjects with **Type 2 Diabetes Mellitus**.

25. An Open-Label Study to Examine the Long-Term Effect on Glucose Control (Hgb A1C), Safety, and Tolerability of XXX Given Two Times a Day to Subjects with **Type 2 Diabetes**.

26. A Multi-Center Study to Determine the Exposure to **Cigarette Smoke** of Adult U.S. Smokers, who Spontaneously Switched to Lower or Higher FTC Tar Delivery Cigarettes, Phillip Morris USA Inc.

27. A Double-Blind, Randomized, Parallel Group Study, to Evaluate the Safety, Tolerability, and Efficacy of XXX, Alone or Co-administered with Atorvastatin, in Subjects with Primary **Dyslipidemia.**

28. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Examine Safety and Pharmacokinetics of XXX Long-Acting Released, Administered Weekly in Subjects with **Type 2 Diabetes Mellitus.**

29. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Study to Assess the Safety and Efficacy of FS-67 in Subjects with **Muscle Strain.**

30. Clinical Utility of XXX in Simultaneously **Achieving Blood Pressure and Lipid Endpoints** in a Specific Population. (CAPABLE).

31. A Phase III, Multi-Center, Randomized, Double-blind, Placebo-Controlled Study of the Effect of Daily Treatment with XXX on Measures of Cognitive and Global Function in Subjects with **Mild-to – Moderate Dementia of the Alzheimer's Type.**

32. A Phase III, Investigator-Blind, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of XXX Sprinkle PO QD for 7 Days Compared to Penicillin VK 10mg/kg PO QID for 10 Days in the **Treatment of Tonsillitis and/or Pharyngitis Secondary to Streptococcus Pyogenes in Pediatric Patients.**

33. An Open-Label Study of the Efficacy and Safety of 5mg and 10mg XXX in Patients with **Overactive Bladder Symptoms.**

34. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Examine Safety and Pharmacokinetics of XXX Long-Acting Release Administered Weekly in Subjects with **Type 2 Diabetes Mellitus.**

35. A Multi-Center, Placebo-Controlled, Randomized, Double-Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontopheretic Application of Acyclovir 5% Cream with an Open Label Conventional Therapy Treatment Arm , and a Blinded Evaluator, for the Episodic Treatment of **Recurrent Herpes Labialis.**

36. A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXX XR (Extended Release) in Patients with **Restless Leg Syndrome**.

37. A U.S. Randomized Questionnaire-Based Trial Assessing the Impact of the Availability of Inhaled Insulin of Therapeutic Choice in Patients with Sub-Optimally Controlled **Type 2 Diabetes.**

38. A 12 Week, Dose-Ranging, Double-Blind, Randomized, Placebo-Controlled, Parallel-group study to Assess the Safety and Efficacy of XXX in **Obese Patients**.

39. Safety and Tolerability of the **Japanese Encephalitis Vaccine** XXX (JE-PIV). Double-Blind, Randomized, Placebo-Controlled Phase III Study.

40. Long Term Immunogenicity of **Japanese Encephalitis Vaccine** XXX (JE-PIV). An Open Uncontrolled Phase III Follow-up Study.

41. A Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of XXX Trap in Subjects with **CIASIS Associated Periodic Syndromes** (CAPS) Using Both Parallel Group and Randomized Withdrawal Designs.

42. Efficacy and Safety of 10mg XXX for Treating Frequent **Heartburn** in Frequent Suffers.

43. A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for XXX (Sumatriptan 85mg/ Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of **Multiple Migraine Attacks**.

44. A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20mg XXX, When used on-Demand for **Pain.**

45. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Safety and Efficacy of XXX in Patients with Mild-to-Moderate **Alzheimer's Disease**.

46. A Double-Blind, Randomized, 6 Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women with **Female Sexual Arousal Disorder (FSAD)**.

47. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled, Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (XXX) Compared with Placebo in the Treatment of **Generalized Anxiety Disorder(Gold Study)**.

48. A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Active – Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (XXX) as Monotherapy in the Treatment of Patients with **Major Depressive Disorder** (Diamond Study).

49. A Double-Blind, Randomized, Placebo-Controlled, Study of the Efficacy, Safety, and Tolerability of 8 Week Treatment of XXX 8mg(QHS) in Sleep Disturbed, Community Dwelling, Mild-to-Moderately Severe **Alzheimer's Disease** Subjects.

50. A Forty-Eight Week, Randomized Discontinuation Trial of Flibanserin in **Women with Hypoactive Sexual Desire Disorder**, Containing an Open-Label Flexible Dose Period, Followed by an Double-Blind, Randomized, Placebo-Controlled Period.

51. A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects with **Mixed Dyslipidemia**.

52. Long-Term, Open-Label, Safety Study of Oral Almotriptan Malate 12.5mg in the Treatment of **Migraines** in Adolescents.

53. The Rembrandt Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed and Flexible XXX Dose Arm Study, to Assess Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Early Stage **Parkinson's Disease**.

54. A Phase II Study Evaluating the Efficacy and Safety of a Unique Intravenous Iron Preparation in the Treatment of **Restless Leg Syndrome (RLS)**.

55. A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium, Alone or in Combination with Hydrochlorothiazide Versus Placebo in **Obese Patients with Elevated Systolic and Diastolic Blood Pressure**.

56. A Validation Study of the **COPD**-PS in a Community Based Sample

57. A Randomized, Open-Label, Multi-Center, Comparator-Controlled, Study to Examine the Effects of Eventide Long-Acting Release on Glucose Control (Hgb A1C) and Safety, in Subjects with **Type 2 Diabetes Mellitus** Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.

58. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of XXX Extended-Release (G-ER) Tablets in the Treatment of Patients with **Post-Herpetic Neuralgia**.

59. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Dosed and Dose Levels of XXX in Female Patients with **Irritable Bowel Syndrome** with Diarrhea.

60. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study of the Efficacy, Tolerability, and Safety of XXX in the Treatment of **Pain** Associated with Tendonitis or Bursitis of the Shoulder, Knee, or Elbow.

61. A Phase III, 24 Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere /Insulin in Combination with Metformin or Technosphere/ Insulin Alone Versus 2 Oral Antidiabetic Agents (Metformin and Secretagogue) in Subjects with **Type 2 Diabetes Mellitus** Sub-Optimally Controlled on Combination Metformin and Secretagogue.

62. A Randomized, Double-Blind, Active-Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of XXX Versus Acyclovir Cream for Treatment of **Recurrent Herpes Simplex Labialis**. A Multinational, Multi-Center Phase III Study.

63. A 24 Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of XXX 50mg and 100mg Each Evening in Premenopausal **Women with Hypoactive Sexual Desire Disorder**.

64. A Multi-Center, Randomized, 1Week, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients with **Major Depressive Disorder**, Who Completed 8 Weeks of Open-Label Treatment with XXX 100mg Once a Day.

65. A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm Placebo and Paroxetine Controlled 8 Week Efficacy Study of 2 Oral Doses of XXX (175mg or 350mg BID) in Adult Outpatients with **Major Depression Disorder**.

66. A 12 Month, Open-Label, Safety Trial of XXX 50mg to 100mg Daily in **Women with Hypoactive Sexual Desire Disorder**.

67. A 104 Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in **Obese Patients**.

68. Effect of Septal Closure of Atrial PFO on Events of **Migraine** with XXX Device.

69. A Phase III, Prospective, Observer-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline Biologicals' XXX, XXX, and XXX Compared to Sanofi Pasteur's XXX and XXX, When Administered as a **Booster Vaccine** in Adults Aged 19-64.

70. A Multi-Center, Open-Label, Study of the Safety and Efficacy of Long Term Use of XXX Extended Release (G-ER) Tablets in the Treatment of Patients with **Post-Herpetic Neuralgia**.

71. Gastrointestinal (GI) Randomized Event and Safety, Open-Label, NSAID Study (XXX): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group, Trial of GI Safety of Celecoxib Compared with Non-Selective NSAID Drugs in **Osteoarthritis Patients**.

72. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of XXX in Adult Subjects with **Type 2 Diabetes Mellitus**.

73. Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis **Vaccine** Absorbed in Persons > 65 Years of Age.

74. A clinical Study to Evaluate the Safety and Efficacy of XXX 12 hour 5mg Loratadine Tablet Versus Placebo Tablet in the Treatment of **Allergic Rhinitis**.

75. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel, Dose Ranging Study of the Safety and Efficacy of XXX in Patients with **Painful Diabetic Peripheral Neuropathy**.

76. Open-Label, Multiple Dose Study of the Safety and Efficacy of XXX in Adults with **Pain due to Osteoarthritis** of the Knee.

77. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 day Treatment with XXX 15mg or 30mg Once a Day, in Frequent Nighttime **Heartburn**.

78. A Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability, and Efficacy of XXX in Persons with **Multiple Sclerosis with Cognitive Impairment**.

79. A Double-Blind, Multi-Center, Randomized, Parallel Group, Yearlong Study to Assess the Efficacy and Safety of XXX or XXX of XXX Administered Orally Once Daily with a Reduced Calorie Diet in **Obese Males and Females**.

80. Efficacy and Safety of XXX of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX, on Stable **Type 2 Diabetes Mellitus**: A 12 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial.

81. A Phase III, 53 Week Study on XXX Efficacy and Safety of XXX: 26 Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks), and XXX (26 Weeks) Controlled, Multi-Center Study of XXX, Controlled Safety Follow-Up in Subjects with **Osteoarthritis of the Knee** and 1 Week Post-Treatment Safety Follow-Up.

82. A Phase II Randomized, Double-Blind, Placebo and Positive Controlled, Multi-Center, Parallel Group Proof of Concept Study of the Analgesic Effects of XXX in Adult Patients with **Chronic Low Back Pain.**

83. A Multi-Center, Placebo-Controlled, Randomized, Double-Blind, Subject Initiated, Study of the Safety and Efficacy of Electro kinetic Transdermal System with XXX for the Episodic Treatment of **Recurrent Herpes Labialis**. (ASSESSOR).

84. Double-Blind, Parallel-Group, Comparison of 23mg XXX Sustained Release to 10mg XXX Immediate Release in Patient with Moderate to Severe **Alzheimer's Disease**.

85. Efficacy and Safety of 2mg/day of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX on Stable **Type 2 Diabetes Mellitus**: A 12 Week, Multi-Center Randomized, Double-Blind, Placebo-Controlled Study.

86. Open-Label Study of the Effect of Daily Treatment with XXX in Subjects with **Dementia of the Alzheimer's Type**.

87. A Long Term, Open-Label, Safety Study of XXX (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release) Capsules in Subjects with **Chronic Moderate to Severe Nonmalignant Pain**.

88. A Phase II, Multi-Center, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated **Acute Influenza**.

89. A Randomized, Double-Blind, Phase III, Study of the Efficacy and Safety of XXX in **Subjects Requiring NSAID Treatment.**

90. A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effects of DHA on **Cognitive Functions in the Elderly**.

91. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II/III, Study to Evaluate the Efficacy and Safety of XXX and Placebo Given Orally for 12 Weeks for the Treatment of **Opioid-Induced Constipation** (OIC) in Patients with Chronic Non-Cancer Pain.

92. A Phase III, Randomized, Multi-Center, Double-Blind, Allopurinol-Controlled, Study Assessing the Efficacy and Safety of Oral XXX in **Subjects with Gout**.

93. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center , Study Investigating the Efficacy and Safety of a Fast Dissolving (XXX) Formulation of XXX for the Treatment of **Nocturia in Adults**.

94. A Phase III, Randomized, Active0Controlled, Modified Double-Blind, Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate **Vaccine** Compared to a 23-Valent Polysaccharide Vaccine in Adults 60-64 Years Old who are Naive to 23-Valent Polysaccharide Vaccine.

95. A Randomized-Withdrawal, Phase III, Study Evaluating the Safety and Efficacy of XXX Extended-Release in Subjects with **Painful Diabetic Peripheral Neuropathy**.

96. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Safety and Efficacy of Multiple Doses of XXX Sustained Release, IXXX Sustained Release, and Placebo in **Obese Subjects with Type 2 Diabetes Mellitus**.

97. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose Range Finding, Parallel-Design, Phase II Trial of Oral XXX Administered to Patients with **Irritable Bowel Syndrome** with Constipation.

98. A 2 Week, Randomized, Double-Blind, Placebo and Positive Controlled, Parallel Group, Multi-Center, Study to Assess the Efficacy and Tolerability of XXX in Patients with **Moderate to Severe Pain Due to Osteoarthritis**.

99. Phase II, Randomized, Double-Blind, Placebo and Active Controlled, Multi-Center, Parallel Group, Proof of Concept Study of the Analgesic Effects of XXX in Adult Patients with **Chronic Low Back Pain**.

100. A Multi-Center, Randomized, Double-Blinded, “Crossover” Design Study to Evaluate the lipid altering Efficacy and Safety XXX Combination Tablet Compared to XXX+ Simvastatin Co-administration in Patients with Primary **Hypercholesterolemia and Mixed Dyslipidemia**.

101. A Double-Blind, Randomized, Study to Evaluate the Efficacy and Safety of XXX 50mg or Placebo When Co-Administered with Statins in Subjects with **Hypercholesterolemia**, With an Optional Open-Label Extension.

102. A Phase III, Controlled, Multi-Center, Study to Evaluate Antibody Persistence at 1,3,5, and 10 years following administration of single dose Tdap **Vaccine** to Healthy Subjects, 19 Years of Age and Older in the Study XXX.

103. A Phase III, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate **Vaccine** (13vpnc) When Administered concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults 50-59 Years of Age Who Are Naïve to 23-Valent Pneumococcal Polysaccharide Vaccine and to Evaluate the Immune Response of a Second Dose of 13vpnc Administered 5 Years After Initial 13 vpnc Vaccination.

104. Double-Blind, Parallel-Group, Comparison of 23mg of XXX Sustained Release to 10mg XXX Immediate Release in Patients with **Moderate to Severe Alzheimer’s Disease**.

105. A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study with Open-Label Follow On, to Evaluate the Efficacy, Safety, and Tolerability of PSD502 in Subjects with **Premature Ejaculation (PE)**.

106. Randomized, Double-Blind, Parallel-Group, Multi-Center, Study to Compare the Glycemic Effects, Safety, and Tolerability of XXXX: Long-Acting Release to Those of XXXX and XXXX in Subjects with **Type 2 Diabetes Mellitus** Treated with XXXX.

107. A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of XXXX Compared to Open-Label XXXX in Patients with **Hypercholesterolemia**.

108. A Phase III Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of XXXX to Placebo and Their Single Agent XXXX and XXXX Constituents for the Treatment of **Obesity in Adults**.

109. Evaluation of XXXX on Carotid Intima-Media Thickness in Subjects with Type IIa and IIb **Dyslipidemia** with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial.

110. A Phase III, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Immunogenicity of 2 Dose Series of XXXX **Vaccine** Antigen in Association with AS03 Adjuvant in Adults.

111. A Phase III, Flexible Dose Titration Followed by Randomized Double-Blind Study of Controlled Release XXXX Compared to Placebo in Patients with **Osteoarthritis**.

112. A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of XXXX Administered in Conjunction with XXXX in **Obese and Overweight Subjects**.

113. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXXX for the Treatment of **Hypoactive Sexual Desire Disorder** in Surgically Menopausal Women.

114. A 52 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety And Efficacy of XXXX in **Overweight and Obese Patients.**

115. A One Year Open-Label Study Assessing the Safety and Tolerability of XXXX in Patients with **Major Depressive Disorder**.

116. The Efficacy and Safety of XXXX in the Treatment of **Osteoarthritis of the Knee**.

117. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Study of the Long Term Efficacy of XXXX for the Treatment of **Hypoactive Sexual Desire Disorder** in Postmenopausal Women.

118. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Study of the Safety of Efficacy of XXXX for the Treatment of **Hypoactive Sexual Desire Disorder** in Surgically Menopausal Women.

119. A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of XXX Administered in Conjunction with XXX in **Obese and Overweight Subjects**.

120. A Multi-Center, Randomized, Parallel –Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of XXXX on Weight in **Obese and Overweight Subjects**.

121. A Randomized, Double-Blind, Placebo-Controlled Subjective study to Assess the Efficacy of XXXX in Patients with Primary **Insomnia** Characterized by Difficulty Maintaining Sleep.

122. A Phase I, Open-Label Study to Assess the Safety, Extent, and Route of BMS747158 **Nuclear Imaging Product**.

123. A Long Term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of **Coronary Artery Disease (CAD)** in SPECT and PET.

124. A Phase IV Safety Study to Provide Data on Potential Systematic and Pulmonary Hemodynamic Effects Caused by Administration of XXXX in **Patients who Undergo Right Heart Cardiac Catherization**.

125. A Phase IV Safety Study of Patients with **Cardiovascular Disease** who have Echocardiography with XXXX.

126. A Phase I, Multi-Center, Single Dose Safety Trial to Determine Dosing , Bio distribution, and Safety of LMI 1195-101 in Healthy Subjects and Patients with **Heart Failure** Undergoing Positron Emission Tomography (PET).

127. A Phase III Open-Label, Multi-Center, Trial to Evaluate the Efficacy and Safety of XXXX Myocardial Perfusion Imaging (MPI) in the **Pediatric Population with Kawasaki Disease**.

128. A Phase IV Multi-Center, Open-Label, Follow up Study to Assess Incidence of Nephrogenic Systematic Fibrosis in Patients with Moderate to Severe **Kidney Disease** Undergoing Magnetic Resonance Imaging(MRI) with XXXX in Clinical Practice.

129. Retrospective Observational Database to Compare Mortality in Intensive Care Unit (ICU) **Patients Undergoing Echocardiography** with and without XXXX.

130. A Phase III, Open-Label, Multi-Center, Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of BMS747158 Injection in Patients with Suspected or Known **Coronary Artery Disease (CAD)**.

131. A Multi-Center, Phase II, Open-Label Trial to Determine Optimal Imaging Parameters and Assess the Safety of LMI1195-101 in Heart Failure Subjects.

132. A Phase III, Open-Label, Multi-Center, Single Dose, Study to Assess the Diagnostic Efficacy of BMS747158 in Patients with Suspected of Known **Coronary Artery Disease (CAD)**.

133. A Phase II, Open-Label, Randomized, Multi-Center Study for the Development of One-Day Rest/Stress Cardiac PET perfusion Imaging Protocols in Patients with **Ischemia**.